α-Synuclein in blood cells differentiates Parkinson’s disease from healthy controls

Suaad Abd Elhadi; Jessica Grigoletto; Maura Poli; Paolo Arosio; David Arkadir; Ronit Sharon

doi:10.1002/acn3.50944

α-Synuclein in blood cells differentiates Parkinson’s disease from healthy controls

Suaad Abd Elhadi, Jessica Grigoletto, Maura Poli, Paolo Arosio, David Arkadir, Ronit Sharon^*

^*Corresponding author for this work

Department of Biochemistry and Molecular Biology

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Objective: To determine whether blood cells expressed α-Syn can differentiate Parkinson’s disease (PD) from healthy controls (HC). Methods: The concentrations of α-Syn were determined in samples of blood cell pellets using a quantitative Lipid-ELISA assay. In addition, the levels of total protein, hemoglobin, iron and H-ferritin were determined. The study includes samples from the Biofind cohort (n = 46 PD and 45 HC) and results were validated with an additional cohort (n = 35 PD and 28 HC). Results: A composite biomarker consisting of the concentrations of total α-Syn, proteinase-K resistant (PK^res) α-Syn and phospho-Serine 129 α-Syn (PSer 129), is designed based on the analysis of the discovery BioFIND cohort. This composite biomarker differentiates a PD subgroup, presenting motor symptoms without dementia from a HC group, with a convincing accuracy, represented by an AUC = 0.81 (95% CI, 0.71 to 0.92). Closely similar results were obtained for the validation cohort, that is, AUC = 0.81, (95% CI, 0.70 to 0.94). Interpretation: Our results demonstrate the potential usefulness of blood cells expressed α-Syn as a biomarker for PD.

Original language	American English
Pages (from-to)	2426-2436
Number of pages	11
Journal	Annals of Clinical and Translational Neurology
Volume	6
Issue number	12
DOIs	https://doi.org/10.1002/acn3.50944
State	Published - 1 Dec 2019

Bibliographical note

Funding Information:
Funding information Funding for this study was provided by Michael J. Fox Foundation, grant ID 11899. The authors thank Prof. Norman Grover for statistics consulting.

Publisher Copyright:
© 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

Access to Document

10.1002/acn3.50944

Cite this

@article{40581068129543118edc9330907effd3,

title = "α-Synuclein in blood cells differentiates Parkinson{\textquoteright}s disease from healthy controls",

abstract = "Objective: To determine whether blood cells expressed α-Syn can differentiate Parkinson{\textquoteright}s disease (PD) from healthy controls (HC). Methods: The concentrations of α-Syn were determined in samples of blood cell pellets using a quantitative Lipid-ELISA assay. In addition, the levels of total protein, hemoglobin, iron and H-ferritin were determined. The study includes samples from the Biofind cohort (n = 46 PD and 45 HC) and results were validated with an additional cohort (n = 35 PD and 28 HC). Results: A composite biomarker consisting of the concentrations of total α-Syn, proteinase-K resistant (PKres) α-Syn and phospho-Serine 129 α-Syn (PSer 129), is designed based on the analysis of the discovery BioFIND cohort. This composite biomarker differentiates a PD subgroup, presenting motor symptoms without dementia from a HC group, with a convincing accuracy, represented by an AUC = 0.81 (95% CI, 0.71 to 0.92). Closely similar results were obtained for the validation cohort, that is, AUC = 0.81, (95% CI, 0.70 to 0.94). Interpretation: Our results demonstrate the potential usefulness of blood cells expressed α-Syn as a biomarker for PD.",

author = "{Abd Elhadi}, Suaad and Jessica Grigoletto and Maura Poli and Paolo Arosio and David Arkadir and Ronit Sharon",

note = "Funding Information: Funding information Funding for this study was provided by Michael J. Fox Foundation, grant ID 11899. The authors thank Prof. Norman Grover for statistics consulting. Publisher Copyright: {\textcopyright} 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.",

year = "2019",

month = dec,

day = "1",

doi = "10.1002/acn3.50944",

language = "American English",

volume = "6",

pages = "2426--2436",

journal = "Annals of Clinical and Translational Neurology",

issn = "2328-9503",

publisher = "John Wiley and Sons Inc.",

number = "12",

}

TY - JOUR

T1 - α-Synuclein in blood cells differentiates Parkinson’s disease from healthy controls

AU - Abd Elhadi, Suaad

AU - Grigoletto, Jessica

AU - Poli, Maura

AU - Arosio, Paolo

AU - Arkadir, David

AU - Sharon, Ronit

N1 - Funding Information: Funding information Funding for this study was provided by Michael J. Fox Foundation, grant ID 11899. The authors thank Prof. Norman Grover for statistics consulting. Publisher Copyright: © 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Objective: To determine whether blood cells expressed α-Syn can differentiate Parkinson’s disease (PD) from healthy controls (HC). Methods: The concentrations of α-Syn were determined in samples of blood cell pellets using a quantitative Lipid-ELISA assay. In addition, the levels of total protein, hemoglobin, iron and H-ferritin were determined. The study includes samples from the Biofind cohort (n = 46 PD and 45 HC) and results were validated with an additional cohort (n = 35 PD and 28 HC). Results: A composite biomarker consisting of the concentrations of total α-Syn, proteinase-K resistant (PKres) α-Syn and phospho-Serine 129 α-Syn (PSer 129), is designed based on the analysis of the discovery BioFIND cohort. This composite biomarker differentiates a PD subgroup, presenting motor symptoms without dementia from a HC group, with a convincing accuracy, represented by an AUC = 0.81 (95% CI, 0.71 to 0.92). Closely similar results were obtained for the validation cohort, that is, AUC = 0.81, (95% CI, 0.70 to 0.94). Interpretation: Our results demonstrate the potential usefulness of blood cells expressed α-Syn as a biomarker for PD.

AB - Objective: To determine whether blood cells expressed α-Syn can differentiate Parkinson’s disease (PD) from healthy controls (HC). Methods: The concentrations of α-Syn were determined in samples of blood cell pellets using a quantitative Lipid-ELISA assay. In addition, the levels of total protein, hemoglobin, iron and H-ferritin were determined. The study includes samples from the Biofind cohort (n = 46 PD and 45 HC) and results were validated with an additional cohort (n = 35 PD and 28 HC). Results: A composite biomarker consisting of the concentrations of total α-Syn, proteinase-K resistant (PKres) α-Syn and phospho-Serine 129 α-Syn (PSer 129), is designed based on the analysis of the discovery BioFIND cohort. This composite biomarker differentiates a PD subgroup, presenting motor symptoms without dementia from a HC group, with a convincing accuracy, represented by an AUC = 0.81 (95% CI, 0.71 to 0.92). Closely similar results were obtained for the validation cohort, that is, AUC = 0.81, (95% CI, 0.70 to 0.94). Interpretation: Our results demonstrate the potential usefulness of blood cells expressed α-Syn as a biomarker for PD.

UR - http://www.scopus.com/inward/record.url?scp=85075472110&partnerID=8YFLogxK

U2 - 10.1002/acn3.50944

DO - 10.1002/acn3.50944

M3 - Article

C2 - 31742923

AN - SCOPUS:85075472110

SN - 2328-9503

VL - 6

SP - 2426

EP - 2436

JO - Annals of Clinical and Translational Neurology

JF - Annals of Clinical and Translational Neurology

IS - 12

ER -

α-Synuclein in blood cells differentiates Parkinson’s disease from healthy controls

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this